Registry observation: KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion. (PHASE1, PHASE2, RECRUITING)
ClinicalTrials.gov registry observation, published 2026-11-19T00:00:00+00:00. Registry observation: KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion . (PHASE1, PHASE2, RECRUITING). Source-record fields: {"phase": "PHASE1, PHASE2", "sponsor": "Wuhan KadGeno Biotechnology Co., Ltd", "overall_status": "RECRUITING", "has_results": false, "primary_completion_date": "2027-11-30", "primary_completion_type": "ESTIMATED", "clinical_contract": {"allocation": "NON_RANDOMIZED", "arm_groups": [{"type": "EXPERIMENTAL", "label": "Cohort A Dose Level 1"}, {"type": "EXPERIMENTAL", "label": "Cohort A Dose Level 2"}, {"type": "EXPERIMENTAL", "label": "Cohort B Dose Level 1"}, {"type": "EXPERIMENTAL", "label": "Cohort B Dose Level 2"}], "study_title": "KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .", "interventions": [{"name": "KDTV001", "type": "DRUG", "armGroupLabels": ["Cohort A Dose Level 1", "Cohort A Dose Level 2", "Cohort B Dose Level 1", "Cohort B Dose Level 2"]}], "primary_outcomes": [{"measure": "Phase 1: Incidence of Any Adverse Events (AEs), Treatment related AEs (TRAEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study", "timeFrame": "From enrollment to 2 years after the first dose.", "description": "Percentage of participants with AE/TRAE/SAE in FAS population"}, {"measure": "Phase 2: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and HPV-18 and HPV-52 in Cervical Samples", "timeFrame": "From enrollment to 36 weeks after the first dose.", "description": "Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and HPV-18 and HPV-52 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52."}]}} This record describes a study and its registry status; study outcomes require posted results.
Read the report →